Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

The motivation of re-putting the workers back to the physical work locations has raised deep apprehensions among the disabled workers. The medical recommendation or the treatment regime or the incapacity of a person to carry out some functions may be a direct violation of a coming back to work order to others, leading them to […]

The post The Health Implications of Forced Return-to-Office Policies for Employees With Disabilities appeared first on Medical News Bulletin.

Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

Congratulations! You have started on your journey to feeling better! Learn how to get the best out of iCBT with MNB. 

The post How to Get the Best out of iCBT appeared first on Medical News Bulletin.

The FDA has refused to review Moderna’s application for its messenger RNA-based influenza vaccine, according to the company.
In a press release, Moderna noted that the FDA’s rejection of the vaccine, mRNA-1010, did not come with any safety or efficacy concerns. Instead, in a letter to the company, the FDA said the application lacked an “adequate and well-controlled” study.
The letter, which was signed by Vinay Prasad, MD, MPH, director of the FDA’s Center for Biologics Evaluation and Research (CBER), cited the comparator used to evaluate Moderna’s vaccine as the primary issue. In this case, the

Eylea HD injected every 12 or 16 weeks controls neovascular age-related macular degeneration to a similar extent as Eylea injected every 8 weeks, according to a study published in Ophthalmology.
“To address the need to reduce treatment burden while maintaining visual benefits, an 8 mg formulation of aflibercept was developed to enable the intravitreal delivery of a four times higher molar dose compared with the 2 mg formulation,” Jean-François Korobelnik, MD, professor of ophthalmology at University Hospital of Bordeaux, France, and colleagues wrote. “The results of this

Circulating tumor DNA may be an effective biomarker for stratifying patients with small cell lung cancer who would benefit from more stringent follow-ups and clinical trial participation.
Patients who had higher percentages of TP53 or RB1 mutations in their ctDNA at baseline experienced worse survival outcomes, and those who had greater than 0.1% residual ctDNA disease after completing standard chemoimmunotherapy relapsed at a significantly faster rate than those who achieved at least a 99.89% decline.
“Checking ctDNA pretreatment and after patients have completed their four cycles of

A measles outbreak in South Carolina has become the largest in the United States in more than 30 years.
As of Feb. 10, 933 measles cases have been reported in upstate South Carolina since September. The outbreak has surpassed the 2025 West Texas outbreak as the largest in the U.S. since 1992.
Only 6 weeks into 2026, the CDC has confirmed 733 new measles cases in 20 states, most of which are associated with outbreaks (94%). Two outbreaks from 2025 have continued into 2026, including the one in South Carolina and another on the Arizona/Utah border.
“All of the pieces are in place for another bad

Surgeons completed the first successful implantations of the FineVision HP trifocal IOL in the U.S., according to a press release from BVI.
BVI chief commercial officer Andy Chang told Healio that the FineVision HP IOL was designed to support a high-contrast range of distance, intermediate and near vision under varying light conditions.
“The higher near add power is intentionally optimized to enhance fine-detail near tasks while preserving visual quality and continuity across the full range of vision, including in dim light,” he said.
The IOL received FDA approval in October 2025.
Five surgeons

WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Allen C. Ho, MD, director of retina research at Wills Eye Hospital, said 2026 is going to be a “really big year” in retina.
According to Ho, topline results are expected for tyrosine kinase inhibitors from EyePoint Pharmaceuticals and Ocular Therapeutix. Results are also expected on subretinal gene therapy from AbbVie and Regenxbio on sura-vec for biofactory production of anti-VEGF therapy for neovascular age-related macular degeneration.
“I’m looking forward to these potential management-changing

Click here to read the Cover Story, “’Be sensible’ in treatment of ACL-MCL injuries.”
Early in my career, I treated grade 3 MCL injuries in conjunction with ACL tears with early surgery and suture anchor repair.
However, I was not consistently pleased with the rate of motion loss and residual MCL laxity. From treating isolated high grade 3 MCL injuries during the last 25 years, I have learned that these have a high capacity to heal without surgery. I have even had some distal Stener-like MCL injuries that ended up completely stable without surgery.
I began to incorporate autograft or allograft

A behavioral nudging tool may help nephrologists jumpstart conversations about conservative kidney management, according to study data published in Kidney360.
The idea for the tool arose from a panel discussion and literature review. Susan P.Y. Wong, MD, MS, associate professor of medicine in the division of nephrology at University of Washington, Seattle, and colleagues found nephrologists had difficulties explaining conservative kidney management (CKM), were unaware of patient values and favored starting dialysis over delaying it.
Their research led them to develop CKM Jumpstart, a one-page,